Avidity Biosciences
10975 N. Torrey Pines Road
Suite 150
La Jolla
California
92037
United States
Tel: 858-401-7900
Website: http://www.aviditybiosciences.com/
Email: info@aviditybio.com
About Avidity Biosciences
63 articles with Avidity Biosciences
-
Avidity Biosciences Reports First Quarter 2022 Financial Results and Recent Highlights
5/10/2022
Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced financial results for the first quarter ended March 31, 2022 and highlighted recent corporate progress.
-
Avidity Biosciences Expands Role of Michael MacLean to Chief Financial and Chief Business Officer
4/5/2022
Avidity Biosciences, Inc., a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, announced that Michael MacLean, currently the chief financial officer, has expanded his role to include responsibilities as chief business officer.
-
Avidity Biosciences Announces Upcoming Presentations at the American Academy of Neurology 2022 Annual Meeting
3/29/2022
Avidity Biosciences, Inc. today announced they will be presenting at the American Academy of Neurology 2022 Annual Meeting in Seattle, Washington , April 2-7, 2022.
-
Avidity Biosciences Announces Upcoming Presentations at the 2022 MDA Clinical & Scientific Conference
3/7/2022
Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced they will be presenting an oral presentation and multiple poster presentations at the 2022 MDA Clinical & Scientific Conference.
-
Avidity Biosciences Reports Fourth Quarter and Year-End 2021 Financial Results and Recent Highlights
3/1/2022
Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today reported financial results for the fourth quarter and year ended December 31, 2021 and highlighted recent corporate progress.
-
Avidity Biosciences Appoints Steve Hughes, M.D., as Chief Medical Officer
2/23/2022
Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced the appointment of Steve Hughes, M.D. as chief medical officer.
-
Five Top CEOs to Watch in 2022
2/23/2022
Several CEOs have stood out from their peers throughout the past year, winning recognition from the Healthcare Technology Report. BioSpace looks at five of these leaders. -
Avidity Biosciences to Participate in Upcoming Investor Conferences - Feb 11, 2022
2/11/2022
Avidity Biosciences, Inc., a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, announced that the Avidity management team will be participating at the following conferences.
-
Avidity Biosciences Highlights FSHD Program at Virtual Investor and Analyst Event
12/9/2021
Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced it will be hosting a live webcast investor and analyst day event titled "Volume 3: Delivering on AOCs - FSHD" at 11:00am ET.
-
Avidity Biosciences Reports Third Quarter 2021 Financial Results and Recent Highlights
11/9/2021
Avidity Biosciences, Inc. (Nasdaq: RNA), today reported financial results for the third quarter and nine months ended September 30, 2021 and highlighted recent corporate progress.
-
Clinical Catch-Up: November 1-5
11/8/2021
The first week of November was marked by numerous clinical trial announcements. Here’s a look. -
Avidity Announces First Person Dosed with an Antibody Oligonucleotide Conjugate (AOC™)
11/4/2021
Avidity Biosciences, Inc., a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, announced that the first participants in the Phase 1/2 MARINA trial have been dosed with Avidity's lead AOC product candidate, AOC 1001, marking the first time a person has been dosed with an AOC.
-
Avidity Biosciences to Participate in Upcoming Investor Conferences - Nov 02, 2021
11/2/2021
Avidity Biosciences, Inc. a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, announced that the Avidity management team will be participating at the following conferences.
-
FDA Grants Fast Track Designation to AOC 1001 for the Treatment of Myotonic Dystrophy Type 1
10/18/2021
Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to its lead program, AOC 1001, for the treatment of myotonic dystrophy type 1 (DM1).
-
Avidity Biosciences to Participate in Upcoming Investor Conferences - Aug 31, 2021
8/31/2021
Avidity Biosciences, Inc. a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, announced that the Avidity management team will be participating at the following conferences
-
European Medicines Agency (EMA) Grants Orphan Designation for AOC 1001
8/24/2021
Avidity Biosciences, Inc., a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, announced that the European Commission has granted orphan designation for AOC 1001.
-
Avidity Biosciences Enters Into Collaboration with FSHD Clinical Trial Network to Support Development of Biomarkers for Future Clinical Trial Use
8/16/2021
Avidity Biosciences, Inc. today announced its collaboration with the Facioscapulohumeral Muscular Dystrophy (FSHD) Clinical Trial Research Network (FSHD CTRN) to support a natural history study for people living with FSHD called the Motor Outcomes to Validate Evaluations Plus (MOVE+) Study.
-
Avidity Biosciences Reports Second Quarter 2021 Financial Results and Recent Highlights
8/9/2021
Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today reported financial results for the second quarter and six months ended June 30, 2021 and highlighted recent corporate progress.
-
Avidity Biosciences, Inc. Announces Pricing of Public Offering of Common Stock
8/3/2021
Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced the pricing of an underwritten public offering of 8,000,000 shares of its common stock at a price to the public of $18.00 per share.
-
Avidity Biosciences, Inc. Announces Proposed Public Offering of Common Stock - Aug 02, 2021
8/2/2021
Avidity Biosciences, Inc., a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, announced that it intends to offer and sell, subject to market and other conditions, $100 million of shares of its common stock in an underwritten public offering.